Allogeneic vs Autologous Cell Therapies: CAR-T & Beyond

Time: 10:00 am
day: Focus Day - Track A - Morning


  • How allogeneic T-cell therapies overcome limitations associated with autologous approaches available today
  • Potential benefits of allogeneic EBV T-cells to address medical need in EBV driven cancers and auto-immune diseases as well as a platform for allogeneic CAR-T providing safety and efficacy with no need for gene editing TCR or HLA